DiaMedica Therapeutics Statistics
Total Valuation
DMAC has a market cap or net worth of $428.36 million. The enterprise value is $376.25 million.
Important Dates
The next estimated earnings date is Monday, March 16, 2026, after market close.
| Earnings Date | Mar 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DMAC has 53.58 million shares outstanding. The number of shares has increased by 13.70% in one year.
| Current Share Class | 53.58M |
| Shares Outstanding | 53.58M |
| Shares Change (YoY) | +13.70% |
| Shares Change (QoQ) | +15.53% |
| Owned by Insiders (%) | 47.29% |
| Owned by Institutions (%) | 23.86% |
| Float | 24.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.54 |
| P/TBV Ratio | 8.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.67, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.67 |
| Quick Ratio | 10.55 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.12% and return on invested capital (ROIC) is -41.91%.
| Return on Equity (ROE) | -64.12% |
| Return on Assets (ROA) | -38.33% |
| Return on Invested Capital (ROIC) | -41.91% |
| Return on Capital Employed (ROCE) | -64.90% |
| Weighted Average Cost of Capital (WACC) | 10.51% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.14M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DMAC has paid $27,000 in taxes.
| Income Tax | 27,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.35% in the last 52 weeks. The beta is 1.14, so DMAC's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | +42.35% |
| 50-Day Moving Average | 8.32 |
| 200-Day Moving Average | 5.96 |
| Relative Strength Index (RSI) | 53.00 |
| Average Volume (20 Days) | 248,326 |
Short Selling Information
The latest short interest is 4.23 million, so 7.89% of the outstanding shares have been sold short.
| Short Interest | 4.23M |
| Short Previous Month | 4.09M |
| Short % of Shares Out | 7.89% |
| Short % of Float | 16.93% |
| Short Ratio (days to cover) | 13.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.60M |
| Pretax Income | -31.90M |
| Net Income | -31.93M |
| EBITDA | -33.56M |
| EBIT | -33.60M |
| Earnings Per Share (EPS) | -$0.72 |
Full Income StatementBalance Sheet
The company has $55.32 million in cash and $266,000 in debt, with a net cash position of $55.05 million or $1.03 per share.
| Cash & Cash Equivalents | 55.32M |
| Total Debt | 266,000 |
| Net Cash | 55.05M |
| Net Cash Per Share | $1.03 |
| Equity (Book Value) | 51.62M |
| Book Value Per Share | 0.99 |
| Working Capital | 50.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.73 million and capital expenditures -$41,000, giving a free cash flow of -$27.77 million.
| Operating Cash Flow | -27.73M |
| Capital Expenditures | -41,000 |
| Free Cash Flow | -27.77M |
| FCF Per Share | -$0.52 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DMAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.70% |
| Shareholder Yield | -13.70% |
| Earnings Yield | -7.40% |
| FCF Yield | -6.44% |
Analyst Forecast
The average price target for DMAC is $15.50, which is 93.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | 93.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -10.25% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 15, 2018. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 15, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
